|
|
Post by peppy on Nov 10, 2021 12:14:09 GMT -5
I hope some of yesterdays analysts are going to ask questions on the call.
Yesterdays earnings call was a, Jeez Louise.
|
|
|
|
Post by BD on Nov 10, 2021 12:14:22 GMT -5
I or liane will open the shoutbox again a bit before 5pm EST.
|
|
|
|
Post by sayhey24 on Nov 10, 2021 12:18:39 GMT -5
Any idea what the agenda is? Nope, no idea on agenda. I was going to just listen in. I can submit 2 questions if there is someone who cannot attend that would like to ask something. They are limiting questions to 2 per caller, submitted ahead of time, "to allow us to manage the call thematically." Let me know your question(s) and I reserve the right to pick the best 2 IMO.  The call is set up on an audio bridge with unique per participant registration information for the meeting room (i.e., not shareable call information). Here is the current agenda based on shareholder input Stockholder Topics and Q&A: - Afrezza - UTHR & Tyvaso DPI - Pipeline & Business Development - Sales Leaseback & UOP - Shareholder Value |
|
|
|
Post by liane on Nov 10, 2021 12:54:41 GMT -5
So is there a link we can listen in on?
|
|
|
|
Post by wyattdog on Nov 10, 2021 13:04:48 GMT -5
|
|
|
|
Post by mango on Nov 10, 2021 13:21:34 GMT -5
• MannKind focused on being a “realtime control Company” with Afrezza data
• MannKind will pursue discussions with FDA how to best update Afrezza label to better reflect the dosing
• MannKind has started a “Seeing is Believing” challenge with 160 new doctors for Afrezza
• MannKind has been accepted into FDA’s MIDD Pilot program (Model Informed Drug Development Program). MannKind hopes this will help change Afrezza label
• Thirona partnership is progressing and formulation work is complete. Will begin PK/PD study soon
• Clofazimine Phase 1 Initiation this quarter and pre-IND data looks phenomenal
• It appears Receptor will be initiating Cannabidiol Technosphere Phase 1 soon it
|
|
|
|
Post by mango on Nov 10, 2021 13:33:21 GMT -5
MannKind is in a fantastic position. Can’t wait for next year!
|
|
|
|
Post by mango on Nov 10, 2021 13:34:45 GMT -5
Was anything mentioned about NRx?
|
|
|
|
Post by porkini on Nov 10, 2021 13:58:20 GMT -5
So is there a link we can listen in on? Need to register. Send email to ir@mannkindcorp.com and also Cc... ralinaya@mannkindcorp.com to request a login of your own. |
|
|
|
Post by mymann on Nov 10, 2021 14:12:01 GMT -5
So is there a link we can listen in on? Need to register. Send email to ir@mannkindcorp.com and also Cc... ralinaya@mannkindcorp.com to request a login of your own. [br What's with all this special invitation only crap? Just make it available for everyone. Trying to hide something? |
|
|
|
Post by porkini on Nov 10, 2021 14:18:11 GMT -5
Need to register. Send email to ir@mannkindcorp.com and also Cc... ralinaya@mannkindcorp.com to request a login of your own. [br What's with all this special invitation only crap? Just make it available for everyone. Trying to hide something? I am not trying to hide anything, gave you all the info I've come across. From what I've seen and experienced, they are not denying anyone access, just asking that you register. |
|
|
|
Post by BD on Nov 10, 2021 14:19:20 GMT -5
porkini, it wasn't YOU he was inferring was trying to hide something LOL.
|
|
|
|
Post by mymann on Nov 10, 2021 14:22:55 GMT -5
I meant management. I trust most of our posters giving honest information.
|
|
|
|
Post by Chris-C on Nov 10, 2021 14:49:56 GMT -5
• MannKind focused on being a “realtime control Company” with Afrezza data • MannKind will pursue discussions with FDA how to best update Afrezza label to better reflect the dosing • MannKind has started a “Seeing is Believing” challenge with 160 new doctors for Afrezza • MannKind has been accepted into FDA’s MIDD Pilot program (Model Informed Drug Development Program). MannKind hopes this will help change Afrezza label • Thirona partnership is progressing and formulation work is complete. Will begin PK/PD study soon • Clofazimine Phase 1 Initiation this quarter and pre-IND data looks phenomenal • It appears Receptor will be initiating Cannabidiol Technosphere Phase 1 soon it I read the transcript and wonder how many of these topics will be repeated in today's call?, or will they focus on Q&A that got sabotaged by technical issues yesterday (as they should!)? I was pleased to learn that they are making some gains with Afrezza sales, and they seem to be aware that retention is a key focal point. The dosing recommendations and pilot physician education (seeing is believing) program using CGMs should lead to improved new scripts and refills. I would love to get some specifics on the actual retention rates of new users. I imagine we'd all be shocked, especially since it would be an uphill battle to reach out to former Afrezza users and convince them that a change in dosing will make all the difference. My hunch is they will focus on retaining new users. If half of what MC described about pipeline candidates comes to fruition, we'll be in remarkably better shape by year end 2022. Let's keep our fingers crossed! |
|
|
|
Post by sportsrancho on Nov 10, 2021 14:56:19 GMT -5
I meant management. I trust most of our posters giving honest information. . It started out it was for certain investors only …evidently that changed yesterday. I believe they got a lot of emails concerning the situation. |
|
